Eli Lilly's Antibody Treatment For COVID-19 Gets FDA Emergency Use Authorization

The United States Food and Drug Administration has issued an emergency use authorization for Eli Lilly and Company’s (NYSE: LLY) monoclonal antibody treatment bamlanivimab for use against COVID-19 in both adults and children.What Happened: Under the EUA, the treatment can be distributed and administered intravenously in a single dose by health care providers, according to a statement issued by the FDA.The authorization was given based on data from two Phase 2 trials in 465 non-hospitalized adults showing mild-to-moderate symptoms of COVID-19.The investigational drug is authorized for high-risk patients, including those aged 65 or above, that test positive for SARS-COV-2, as …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.